Semax
Also known as: Semax (ACTH(4-10) analog, Met-Glu-His-Phe-Pro-Gly-Pro)
Semax is a synthetic heptapeptide derived from ACTH(4-10). It is registered as a drug in Russia (1994) for acute ischemic stroke, asthenic states, and optic nerve disease; it is not FDA-approved.
Pricing for Semax
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Semax
40 third-party tests across 18 vendors. Each card links to the full report.
For
Semax
by Crush Research· batch CR-SMX-10-2605-1
For
Semax
by Moglabs· batch SX002
For
Semax
by NG Peptide· batch SMX-09
For
Semax
by Riptide Wellness· batch RWSMX-10-1002
For
Semax
by Peptide Plugs· batch 122-A-S
For
Semax
by Crush Research· batch CR-SMX10-2603-1
For
Semax
by Crush Research· batch CR-SMX10-2603-1
For
Semax
by Peptide Partners· batch SX202603
For
Semax
by Glacier Aminos· batch SMXGA-02
For
Semax
by Peptidegurus· batch 1st Feb 2026
For
Semax
by Mile High Compounds· batch SMX-010-MH-04
For
Semax
by Ascension Peptides· batch 30-01260229
For
Semax
by Peptide Supply Co.· batch PSCSMX10001
For
Semax
by MedGe Peptides· batch SMX30A 12 29 25
For
Semax
by MedGe Peptides· batch SMX30A 12 29 25
For
Semax
by Ion Peptide· batch SK10-010226
For
Semax
by Forge Performance Co.· batch cmp9w4qoq000m9irxllfvoudm
For
Semax
by Simple Peptide· batch SEMX12222025-3
For
Semax
by Ion Peptide· batch SX10-12125
For
Semax
by Sunrise Bioresearch· batch SMX10NOV25-01
For
Semax
by Ion Peptide· batch SX10-1125
For
Semax
by Glacier Aminos· batch SMXGA01
For
Semax
by Glacier Aminos· batch SMXGA01
For
Semax
by Ion Peptide· batch SMX10-1025
13 citations indexed for Semax
Study · 2026
Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study
Background: Management of skeletal Class III malocclusion of maxillary origin in late adolescence remains challenging, as conventional tooth-borne orthopedic approaches show reduced effectiveness at advanced stages of skeletal maturation.
Study · 2026
Multi-Layer Magnetic Shields Based on Fe-Based Nanocrystalline and Co-Based Amorphous Ribbons
We constructed a multi-layer composite magnetic shield composed of Fe-based nanocrystalline (FN) and Co-based amorphous (CA) ribbons, and focused on the influence of the number of layers and their arrangement on the shielding effectiveness (SE).
review · 2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Background Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.
review · 2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine.
review · 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
animal · 2025
The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease
Alzheimer's disease, first described over a century ago, is currently among the most common neurodegenerative diseases whose significance is increasingly growing with the aging of populations.